Objective-Bone Gla Protein (BGP, osteocalcin) is commonly present in the calcified vasculature and was recently shown as energy metabolism-regulating hormone. This study investigates the role of BGP in cartilage and vasculature mineralization. Methods and Results-We established an in vitro BGP-overexpression model in chondrocytes (ATDC5) and vascular smooth muscle cells (MOVAS). BGP overexpression upregulated markers of chondrogenic differentiation and intensified staining for minerals. BGP overexpression enhanced glucose uptake and increased expression of glucose transporters and glycolysis enzymes while decreasing gluconeogenesis enzymes. Treatment with purified BGP activated insulin signaling pathway and upregulated genes of glucose transport and utilization. Both BGP overexpression and treatment with purified BGP resulted in stabilization of hypoxia-inducible factor 1␣ (HIF-1␣) in chondrocytes and vascular smooth muscle cells, shown essential in mediating the direct metabolic effect of BGP. The in vivo model of 1,25(OH) 2 D 3 -induced vascular calcification in rats revealed a correlation between calcification, elevated BGP levels, and increased HIF-1␣ expression in aortas and bone growth plates. The in vivo introduction of BGP siRNA, coadministered with 1,25(OH) 2 D 3 , prevented 1,25(OH) 2 D 3 -induced HIF-1␣ stabilization, and diminished osteochondrogenic differentiation and mineralization of aortas. Conclusion-This study demonstrates novel mechanism by which BGP locally shifts cells toward glycolytic breakdown of glucose, in a HIF-1␣-dependent manner, and stimulates calcification of cartilage and vasculature. (Arterioscler Thromb Vasc Biol. 2011;31:e55-e71.)
V ascular calcification is common in the pathophysiology of human arteries and heart valves and is associated with aging and several disease states, among them atherosclerosis, osteoporosis, chronic kidney disease, and diabetes. 1, 2 For many years, vascular calcification was thought to occur via a passive, degenerative mechanism of calcium phosphate precipitation; recently, however, it has re-emerged as an active, cell-mediated process resembling cartilage and bone formation. [1] [2] [3] [4] Numerous factors were implicated in the initiation of vascular calcification, such as elevated phosphate, parathyroid hormone, bone morphogenic proteins (BMPs), glucose, and active vitamin D 3 (1,25(OH) 2 D 3 ). The major hypothesis argues that vascular calcification is a consequence of the phenotypic transformation of vascular smooth muscle cells (VSMCs) into bone or cartilage-like cells, capable of releasing apoptotic bodies and mineralization-competent matrix vesicles, which form a nidus for calcium crystal formation. 2,4 -6 Depending on the environment, these vesicles can be loaded with mineralization-inhibiting proteins, such as Matrix Gla Protein and fetuin-A, which limit their mineralization potential. 2,4 -6 In addition to vesicle release, VSMCs, and chondrocytes, which arise from a common progenitor mesenchymal stem cell, share the capacity to express osteochondrogenic markers. 2, 7 VSMCs residing in the calcified blood vessels, including arteries from uremic patients, show a downregulaton of typical smooth muscle markers (␣SM-actin and ␣-SM22), concomitant with upregulation of bone-related markers such as alkaline phosphatase (ALP), BMP, osteopontin, osterix, and Bone Gla Protein (BGP) at the calcification loci. 8 -10 Similarly, VSMCs have been shown to express the chondrocyte-specific transcription factor Sox9 and the matrix protein collagen type II in the calcified aortas of rats with chronic renal failure, as well as in human aortic tissue. 11, 12 Although some of these proteins have been reported to function as either inducers or inhibitors of skeletal and vascular mineralization, the role of others, such as BGP, remains unclear. BGP, also known as osteocalcin, is the most abundant noncollagenous protein in the bone. It undergoes vitamin K-dependent post-translational modification, where 3 glutamic acid (Glu) residues are ␥-carboxylated (Gla). Newly synthesized ␥-carboxylated BGP binds with high affinity to bone hydroxyapatite mineral, although a fraction is released into the circulation. Although BGP is widely used in clinics as a marker of bone turnover, analysis of BGP through lossand gain-of-function experiments in mice did not confirm its contribution to matrix mineralization. 13 Recent advances in bone research have identified a new role for BGP in the regulation of energy metabolism. 14, 15 Analysis of transgenic mouse models, including BGP Ϫ/Ϫ , Esp Ϫ/Ϫ , and FoxO1 ob Ϫ/Ϫ , revealed a systemic effect of BGP on glucose metabolism, via stimulation of insulin production and secretion from the pancreas, and secretion of adiponectin, an insulin-sensitizing adipokine, from the adipose tissue. 16 -20 Nevertheless, it is not known whether BGP affects the metabolic state of other cells, such as chondrocytes and VSMCs, locally.
Growth-plate cartilage is considered to be a highly metabolic tissue, adapted to generating energy for bone growth in its poorly vascularized and hypoxic (Ͻ5% O 2 ) environment. Residing chondrocytes progress from proliferative layer to postmitotic hypertrophic stage and, in addition to acquiring a unique phenotype, change their energy status from oxidative metabolism to anaerobic glycolysis. 21 One mechanism by which chondrocytes sense and metabolically adapt to low O 2 tension is via stabilization of hypoxia-inducible factor 1 (HIF-1), which is a heterodimer of two proteins, HIF-1␣ and HIF-1␤. 22 Under normoxia, HIF-1␣ is hydroxylated and rapidly degraded by the proteasome. Under hypoxic conditions, hydroxylation of HIF-1␣ does not occur and the ␣ subunit translocates to the nucleus where, on binding to its ␤ counterpart, it triggers the expression of a plethora of genes involved in glucose metabolism, angiogenesis, and differentiation, among others. 22, 23 In the skeletal context, HIF-1␣ has been shown to be essential for chondrocyte survival in vivo, because conditional deletion of HIF-1␣ results in strikingly increased proliferation and widened and misshaped growth plates. 24 The notion that physiologically and ectopically mineralized tissues are enriched with BGP led us to investigate the role of BGP in cartilage and vasculature matrix calcification. In light of the recently discovered metabolic role of BGP, we studied its ability to exert local regulation of glucose metabolism in chondrocytes and VSMCs, by altering cell metabolic status. We compared the effect of BGP overexpression in a mouse chondrocyte cell line (ATDC5) and VSMCs (MO-VAS) on osteochondrogenic differentiation, mineralization, and glucose metabolism in vitro. We further validated the role of BGP as glucose metabolism and mineralizationmodulating factor in the aorta and tibial growth plate using the in vivo siRNA silencing approach in the 1,25(OH) 2 D 3induced model of vascular calcification in young rats. Our results suggest that BGP promotes cartilage and vasculature calcification and increases glucose metabolism through a HIF-1␣-dependent mechanism.
Materials and Methods

Cell Culture
Cells were maintained at 37°C in humidified incubator with 5% CO 2 . Fresh medium was replaced twice a week. ATDC5 cells were kindly provided by Dr. Galia Gat-Yablonski, and MOVAS cells were purchased from ATCC. ATDC5 were cultured in DMEM/F-12 medium (Bet-Haemek) supplemented with 5% fetal bovine serum, 1% insulin-transferrin-sodium selenite (Sigma-Aldrich), penicillin (100 U/mL)/streptomycin (0.1 mg/mL), and 4 mmol/L L-glutamine. MOVAS were cultured in DMEM medium (4.5 g/L glucose) supplemented with 10% fetal bovine serum, penicillin (100 U/mL)/ streptomycin (0.1 mg/mL), 1.5 g/L sodium bicarbonate, 0.2 mg/mL G418, and 4 mmol/L L-glutamine. To induce calcification, we cultured MOVAS in DMEM medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL)/streptomycin (0.1 mg/mL), 10 mmol/L sodium pyruvate, 0.2 mg/mL G418, 4 mmol/L L-glutamine, 10 mol/L insulin, 50 g/mL ascorbic acid, and 10 mmol/L ␤-glycerophosphate. 25 Reactive oxygen species and reactive carbonyl species cell lines were maintained in DMEM medium (Bet-Haememk) supplemented with 10% fetal bovine serum, penicillin (100 U/mL)/streptomycin (0.1 mg/mL), and 4 mmol/L L-glutamine.
BGP Site Directed Mutagenesis and Overexpression
Full-length mouse BGP cDNA was PCR-amplified using primers: (forward) CAGACCTAGCAGACACCATGA, (reverse) CTGCCA-GAGTTTGGCTTTAGG, and cloned into PGEM-T Easy Vector (Promega) according to manufacturer's instructions. PGEM-T BGP construct was later cleaved with EcoRI and BGP inserts were cloned into either pcDNA3 plasmid or pBABE Puro plasmid, conferring neomycin (G418) or puromycin resistance, respectively. BGP mutant in its carboxylation site was generated by substituting 3 glutamic acids (GLU13, GLU17, and GLU20) with aspartic acids in the full-length mouse BGP cDNA by site-directed mutagenesis (QuikChange, Stratagene). The following mutagenic primers were used: (forward) CCAGATCCCCTGGACCCCACCCGGGAC-CAGTGTGACCTTAACCCTGC, (reverse) GCAGGGTTAAGGT-CACACTGGTCCCGGGTGGGGTCCAGGGGATCTGG. The constructs were transformed into JM109 competent cells (Promega) and purified using HiSpeed plasmid midi kit (Qiagen). Insert orientation was verified by PCR and sequencing (HyLabs). Twenty-four hours before transfections cells were seeded at 1ϫ10 5 cells/well in 6-well plates. pcDNA3 ϩBGP construct was transfected into ATDC5 cells and pBABE ϩ BGP was transfected into MOVAS cells using TransIT-LT1 reagent (Mirus). BGP stable ATDC5 colonies were selected with 100 g/mL G418 (Sigma) and BGP stable MOVAS colonies were selected with 10 g/mL Puromycin (Sigma). Stable BGP-wt, BGP-mutant, and empty vector control ATDC5 and MO-VAS cells were cultured in 12-well plates at initial density of 5ϫ10 4 cells/well for 1, 7, 12, and 21 days. Cells were treated twice weekly with 100 mol/L warfarin dissolved in normal media.
BGP and HIF Protein Levels: Immunocytofluorescence, ELISA, and Western Blotting
For BGP immunocytofluourescence, ATDC5 and MOVAS were grown on round glass cover slips inserted into 12-well plates for 7 to 14 days until nodules formed. Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS for 20 minutes and washed twice with PBS for 5 minutes. Blocking was performed with 5% BSA (Sigma-Aldrich), 0.1% Triton-X buffer for 30 minutes, followed by incubation with primary rabbit anti-mouse BGP 1:100 (Santa Cruz) in blocking buffer for 1.5 hours. After three 5-minutes washes in PBS, cells were incubated with secondary FITC-conjugated donkey anti-rabbit 1:200 (Jackson ImmunoResearch) in PBS for 1 hour. Cells were washed 3 times in PBS and coverslips were mounted on slides using DAPI-containing UltraCruz Mounting Medium (Santa Cruz). Fluorescence was observed under Nikon Eclipse E400 micro-scope equipped with Olympus D71 camera and cellÂ software. For Western Blotting, medium was collected and cells were lysed using SBN buffer: 1 mmol/L EDTA, 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 10% Glycerol, 1% NP40, pH 7.5 containing protease inhibitor cocktail (Sigma-Aldrich). After 15 minutes incubation on ice, cell lysates were collected, centrifuged at 12,000 g for 15 minutes and supernatants were stored at -20°C. Total protein quantification was performed using BCA protein assay kit (Thermo Scientific). Equal amounts of protein (50 g) were heated in 1ϫ loading buffer containing 1% DTT at 100°C for 5 minutes, subjected to 15% SDS-PAGE, transferred to nitrocellulose membrane (Whatman). For BGP levels, membranes were blocked with 5% donkey serum in TBSϩT, incubated overnight with primary goat anti-mouse BGP 1:1000 (Santa Cruz) in blocking buffer, washed in TBSϩT and incubated with secondary donkey anti-goat 1:10000 (Santa Cruz) in TBSϩT for 1.5 hours. To ensure specificity of signal, we used an alternative pair of antibodies as well: primary rabbit anti-mouse BGP (Millipore) and secondary goat anti-rabbit (Santa Cruz). For HIF-1␣ levels, a set of primary mouse monoclonal HIF1-␣ antibody 1:1000 (R&D systems) in 5% BSA in TBSϩT and secondary goat antimouse 1:5000 (Jackson ImmunoResearch) was used. 26 Signal was developed with ECL Luminol Reagent (Santa Cruz). BGP levels in cell mediums were identified by Western Blot and by ELISA using Mouse Osteocalcin EIA kit (Biomedical Technologies), according to manufacturer's instructions.
Staining With Alizarin Red, Alcian Blue, and Alkaline Phosphatase
BGP stable and empty vector stable control ATDC5 and MOVAS cells were cultured in 12-well plates at initial density of 5ϫ10 4 cells/well for 1, 7, 12, and 21 days. At collection time points, medium was removed and cell layers were fixed in 4% paraformaldehyde in PBS for 20 minutes. Cells were washed and stored in PBS at 4°C until staining. Samples from the complete series (days 1 to 21) were stained together. For ALP activity, cells were equilibrated with basic buffer: 0.1 mol/L Tris-HCl, 0.1 mol/L NaCl, 0.05 mol/L MgCl 2 , pH 9.5 for 5 minutes. Later, cells were exposed to basic buffer containing NBT/BCIP (Roche) in the dark until the development of color. For Alizarin Red, cells (and aortas from animal experiment) were stained with 0.5% Alizarin Red, pH 4.2 solution for 30 minutes. For Alcian Blue, cells were stained with 0.6% Alcian Blue solution for 30 minutes. On the completion of each staining protocol layers were rinsed in PBS. 27
In Vitro Silencing of HIF-1␣ and BGP
HIF-1␣ was silenced using mouse HIF-1␣ siRNA (Santa Cruz or Thermo Scientific), which is a pool of target-specific 20 to 25 nt siRNAs. Scrambled fluorescein conjugate siRNA (Santa Cruz) was used as control. ATDC5 and MOVAS cells were seeded at 5ϫ10 4 cells/well in 6-well plates and next day were transfected using siRNA transfection reagent (Dharmacon), according to manufacturer's instructions. BGP was silenced using rat BGP siRNA (ON-TARGETplus SMART pool, Thermo Scientific) and nontargeting pool siRNA as control (ON-TARGETplus, Thermo Scientific). Reactive carbonyl species and reactive oxygen species cells were seeded at 5ϫ10 4 cells/well in 6-well plates and next day were transfected using jetPRIME in vitro DNA and siRNA transfection reagent (Polyplus), according to manufacturer's instructions. Downregulation of BGP and HIF-1␣ was verified by real-time PCR and Western Blotting using procedure described above.
Treatment With Purified BGP and Western Blotting of Insulin Transduction Pathway
Twenty-four hours following transfection, the cells were treated with 100 nmol/L purified bovine BGP (Thermo Scientific) diluted in normal ATDC5 or MOVAS medium, respectively, for 0, 5, 10, 15, 30, and 60 minutes. Cells were immediately lysed for total protein (described above) or treated with TRI-reagent for total RNA extraction (described below). Activation of insulin signal transduction pathway was assessed by Western Blotting using primary antibodies for p-IR␤ (Cell Signaling), p-IRS-1 (Millipore), p-Akt (Cell Signaling), IRS-1 (Invitrogen), and Akt (Cell Signaling) all diluted 1:1000 in 5% BSA in TBSϩT and secondary antibody goat anti-rabbit (Santa Cruz) diluted 1:10000 in TBSϩT.
Gene Quantification With Real-Time PCR
RNA was extracted using TRI-reagent (Sigma-Aldrich) according to manufacturer's instructions. One g of total RNA was reversed transcribed using High Capacity cDNA kit (Applied Biosystems). 
XTT Proliferation Assay
ATDC5 and MOVAS (empty vector control and BGP overexpressing) cells were seeded at densities ranging from 0.6 to 3ϫ10 4 cells per well in 96-well plates. Metabolic activity was measured the following day, using XTT kit (Biological Industries) according to manufacturer's instructions.
Glucose Uptake Measurements Using Fluorescence-Activated Cell Sorter
A protocol for glucose uptake was adapted from the previously described method. 29 ATDC5 and MOVAS (empty vector control and BGP overexpressing) cells were seeded at 1ϫ10 5 cells per well in 6-well plates. The next day, medium was replaced with 1 mL of 10 mol/L fluorescent D-glucose analog 2-NBDG (Invitrogen) diluted in PBS. Two-NBDG shows excitation maxima near 470 nm and emission near 550 nm. Incubations were performed at room temperature for 5 to 60 minutes range of time points. Uptake was stopped by removing the 2-NBDG solution, washing twice with ice-cold PBS and resuspending the cells in 0.5 mL of PBS in fluorescence-activated cell sorter (FACS) tubes. For microscopy imaging, 0.1 mmol/L 2-NBDG was used and cells were immediately observed under Nikon Eclipse TS100 fluorescent microscope on the completion of the washing step. Tubes were maintained on ice until FACS analysis was performed within 30 minutes. For each measurement, data from 10,000 single cell events was collected using FACSCalibur machine (Becton Dickinson Immunocytometry Systems). FL1 histogram plot was used to measure incorporated 2-NBDG fluorescence intensity. Each time-point was repeated 3 times in 6-well plate.
In Vivo Calcitriol Treatment and BGP Silencing
The studies were approved by the Hebrew University of Jerusalem Animal Care and Use Committee. Male Sprague-Dawley rats (75 g, 4 weeks old) were purchased from Harlan Laboratories (Rehovot, Israel) and fed a normal chow diet. Two experiments were performed. During first experiment, the rats were randomly allocated into 2 groups: (1) received IP injections of 2.4% (v/v) ethanol in saline vehicle, daily for 7 days (nϭ6); (2) received IP injections of 1 g/kg 1,25(OH) 2 D 3 daily for 7 days (nϭ6). Both groups also received an IP injection of 40 mg/kg calcein on day 5. During the second experiment, similar to above in weight and age rats were allocated into 2 groups: (1) received IP injections of 1 g/kg 1,25(OH) 2 D 3 daily for 7 days and 200 g/kg (15 nmol/kg) scrambled siRNA (ON-TARGETplus nontargeting pool, Thermo Scientific) IV into the tail on days 1, 2, and 5 of the experiment (nϭ3); (2) received IP injections of 1 g/kg 1,25(OH) 2 D 3 daily for 7 days and 200 g/kg (15 nmol/kg) BGP siRNA (ON-TARGETplus SMARTpool, Thermo Scientific) on day 1, 2, and 5 of the experiment (nϭ3). BGP siRNA target sequences are 1.CCCCAAUUGUGAC-GAGCUA; 2.CGAAAGUAUGGACGGCACA; 3.GCACCAC-CGUUUAGGGCAU; 4.GGCAGUAAGGUGGUGAAUA. In vivojet PEI delivery reagent (Polyplus) was used according to manufacturer's instructions. At the end of the experiment (day 8) the animals were anesthetized by Isoflurane and euthanized by cervical dislocation. Tibiae and aortas were removed for histological analysis or RNA extraction, and blood serum was collected.
Histology and Immunohistochemistry
Tissue was fixed overnight in 4% paraformaldehyde (Sigma-Aldrich) in PBS at 4°C. Tibiae were subjected to 3 weeks of decalcification in 0.5 mol/L EDTA, pH 7.4. Following dehydration in graded ethanol solutions and histoclear (Bar-Naor), tissue was embedded in Paraplast, cut into 5-m sections and mounted on Superfrost slides (Thermo Scientific). For Safranin O staining, 0.1% Safranin O (Sigma) solution was used. For immunohistochemistry, sections were deparaffinized in xylene and washed twice with ethanol. Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 (Merck) in methanol for 30 minutes. Sections were rehydrated through a graded series of ethanol solutions, rinsed in PBSϩT, and blocked with 3% goat serum in PBSϩT for 1 hour. Specific antibodies were diluted in 3% goat serum in PBSϩT and incubated for 1 to 2 hours. For BGP immunostaining, a pair of primary rabbit anti-mouse BGP 1:200 (Millipore) and secondary goat anti-rabbit 1:400 (Santa Cruz) was used. For HIF-1␣ immunostaining, a set of primary mouse monoclonal anti-rat HIF1-␣ antibody 1:200 (R&D systems) and secondary goat anti-mouse 1:400 (Jackson ImmunoResearch) was used. HRP activity was measured using DAB substrate (Sigma-Aldrich). 30
Probe Preparation and In Situ Hybridization
Sequences of BGP and PFK (muscle) were PCR-amplified from rat cDNA using specific primers: BGP (F): AGACAAGTCCCACA-CAGCAA; BGP (R): TCCTGGAGAGTAGCCAAAGC; PFK (F): gcccttgtcacctctctgtc; PFK (R): GGCACTGATCTGTTCCAGGT and cloned into PGEM-T Easy Vector (Promega) according to manufacturer's instructions. Sense and antisense digoxigenin-labeled RNA probes for BGP and PFK were transcribed using either T7 or SP6 primers using DIG labeling kit (Roche). Hybridization of 4-m paraffin-embedded sections and visualization with alkaline phosphatase-coupled antidigoxigenin antibodies and indolylphosphate-nitroblue tetrazolium (BCIP/NBT) substrate were performed. Parallel sections were hybridized with antisense and sense probes. Briefly, sections were rehydrated in serial ethanol dilutions, fixed in 4% PFA, and treated with proteinase K (4 g/mL in 0.2 mol/L Tris-HCl, 5 mmol/L EDTA, pH 7.5) for 20 minutes. After digestion, slides were rinsed, fixed again, and acetylated in 0.1 mol/L triethanolamine to reduce hydrogen bonding. RNA probes were dissolved to hybridization buffer (10 mmol/L Tris pH 7.5, 600 mmol/L NaCl, 1 mmol/L EDTA, 0.25% SDS, 10% Dextran Sulfate (American Bioanalytical 50% solution), 1ϫ Denhardt's, 200 g/mL yeast tRNA (Gibco), 50% formamide) for a final concentration of 1 g/mL. Following overnight hybridization at 65°C, slides were incubated with increasing concentrations of SSC to promote denaturing of nucleic acids and then digested with RNAse to eliminate unbound single-stranded RNA. DIG-labeled probes were detected using a polyclonal antidigoxigenin antibody attached to alkaline phosphatase (Roche), which produces color response when it reacts with its substrate NBTϩBCIP (Promega). Endogenous ALP was inhibited with Levamisole (Fluka). In all hybridizations, no signal was observed with sense probes which were used as negative controls.
Hypoxia and CoCl 2 Stimulation
MOVAS cells were seeded at initial density of 1ϫ10 5 cells/well in 6-well plates, cultured under normoxia until 80% confluence and then subjected to either hypoxia (1% O 2 , 94% N 2 , 5%CO 2 ), treatment with 200 mol/L CoCl 2 , or left in normoxia for 24 hours. Modular incubator chamber (Billups-Rothenberg) was used as a hypoxic chamber. HIF-1␣ was silenced using siRNA as described above and subjected to treatment with CoCl 2 24 hours on silencing. Pharmacological inhibition of HIF-1␣ was done by cotreatment with 100 mol/L genistein and 200 mol/L CoCl 2 for 24 hours.
Micro-CT
The region of proximal metaphysis to mid-diaphysis of all femurs was scanned with a Skyscan 1174 X-ray computed microtomograph scanner (Skyscan, Aartselaar, Belgium), equipped with a CCD detector. Images were obtained by 50-kV X-ray tube voltage and 800 A current. Specimens from the 7-day calcitriol experiment were scanned using 0.25 mm aluminum filter, at 3500 ms exposure time and at 13.8-pixel size resolution. For each specimen, a series of 900 projection images were obtained with a rotation step of 0.4°, averaging 2 frames, for a total 360°rotation. Flat field correction was performed at the beginning of each scan for a specific zoom and image format. A stack of 2D X-ray shadow projections was reconstructed to obtain images using NRecon software (Skyscan), and subjected to the morphometric analysis using CTAn software (Skyscan). During reconstruction, dynamic image range, postalignment value, beam hardening, and ring-artifact reduction were optimized for each experimental set. Analysis of the diaphyseal cortical region 200 slices, corresponding to 2.764 mm were chosen. Global grayscale threshold levels for the cortical region between 140 and 255 were selected. For the trabecular region a total of 150 slices, corresponding to 2.073 mm, were selected, and adaptive grayscale threshold levels between 70 and 255 were used. Morphometric analysis was based on the 2D and 3D internal CTAn plug-ins. Additional morphometric parameters were calculated as suggested by recent guidelines for bone microstructure assessment using micro-CT. 31 3D images (CTM file format) were constructed from cortical and trabecular regions of interest, using Marching Cubes 33 algorithm in CTVol software. 32
Statistical Analysis
All data are expressed as meanϮSD. The significance of differences between groups was determined using JMP 8.0 Statistical Discovery Software (SAS Institute 2000) by 1-way ANOVA. Differences between groups were further evaluated by Tukey-Kramer HSD test. Differences were considered significant at PϽ0.05.
Results
1,25(OH) 2 D 3 Induces Vascular Calcification and Upregulates Markers of Osteochnodrogenic Differentiation in Young Rat Aortas
A collection of studies performed on normal and uremic rats demonstrated progression of vascular calcification in adult e58
Arterioscler Thromb Vasc Biol September 2011 animals, on treatment with vitamin D or its analogues. 33, 34 Here we established a model of vascular calcification in the young rats by daily injections of 1 g/kg 1,25(OH) 2 D 3 or vehicle for 7 days. Both groups were injected with calcein (fluorometric dye used for determination of mineral deposition) to assess vascular calcification. Histological analysis revealed that short-term treatment with 1,25(OH) 2 D 3 induces calcification of the descending aorta and neighboring blood vessels, as shown by the Alizarin Red ( Figure 1A) , fluorescent calcein, and Von Kossa ( Figure 1B) staining. Ectopically calcified muscle tissue surrounding vasculature was occasionally observed in the 1,25(OH) 2 D-treated group ( Figure  1D ). Markers typical of cartilage and bone formation have been previously detected in the vicinity of calcified vascular matrix. 2, 5 In current study, real-time PCR analysis showed upregulated expression of osteochondrogenic transcription factors, Sox9 and Runx2, and collagen type II ( Figure 1C ). 1,25(OH) 2 D 3 treatment did not change the levels of smooth muscle markers, alpha smooth muscle actin (␣sm-actin), and smooth muscle 22 ( Figure 1C ). These results demonstrated that short-term treatment with 1,25(OH) 2 D 3 induces vascular calcification and initiates phenotypic transformation in aortic VSMCs.
1,25(OH) 2 D 3 Upregulates BGP in the Aorta and Tibial Growth Plate
BGP gene transcription has been previously reported to be controlled by a 1,25(OH) 2 D 3-responsive element (VDRE) site localized within human and rat, 35 but not mouse 36 gene promoter regions. Moreover, clinical data from vascular calcification in human patients have shown upregulation of BGP, together with other bone-related proteins, at the calcification loci. 8, 10 We used the notion of species-specific control of BGP expression and tested whether in our rat model 1,25(OH) 2 D 3 -induced vascular calcification correlates with BGP accumulation. Although ISH was not sensitive enough to detect BGP mRNA in the aortas (data not shown), real-time PCR showed 25-fold induction in the BGP mRNA expression in the 1,25(OH) 2 D 3 -treated aortas ( Figure 1C ). Immunohistochemical analysis of aortas revealed that concomitant with increased calcification, 1,25(OH) 2 D 3 induces a dramatic elevation in BGP relative to the vehicle-treated group ( Figure 1E ). Histological evaluation of the vehicletreated animals detected BGP mRNA only in the ossified bone and not in the growth plate, whereas BGP was detected in the prehypertrophic and hypertrophic chondrocytes. In the 1,25(OH) 2 D 3 -treated tibiae, BGP expression was more intense in the bone and BGP was detected throughout the growth plate, including proliferative, prehypertrophic, and hypertrophic chondrocytes ( Figure 1F ). These data suggest that 1,25(OH) 2 D 3 results in higher BGP synthesis and secretion by the bone and vasculature.
BGP Expression in the Differentiated VSMCs and Chondrocytes Is Concentrated in Mineralized Nodules
Elevated BGP in ectopically mineralized aortas and physiologically mineralized growth plates raised the possibility of a common role of BGP in matrix mineralization. To investigate this role, we first compared the differentiation and mineralization potential of chondrocytes (ATDC5) and VSMCs (MOVAS). Cells were allowed to differentiate in culture for a period of 1, 7, 14, and 21 days, forming mineralized nodules from day 7 on (Figure 2A ). Most previously reported work characterized the transition of primary VSMCs from contractile to matrix-producing phenotype. We demonstrated for the first time that MOVAS, a VSMC line from murine aorta, is also capable of acquiring an osteochondrocytic phenotype. Immunofluorescent staining demonstrated a high concentration of BGP localized to the mineralized nodules, probably due to being trapped in the matrix by its binding capacity to the hydroxyapatite 35 (Figure 2A) . As BGP is a secreted protein, it was detected by ELISA in ATDC5 and MOVAS cell media ( Figure 2B ). BGP mRNA was present in both cell types and increased over the course of differentiation, reaching 8.4-and 2.8-fold increases in ATDC5 and MOVAS cells, respectively, during the culture period ( Figure 2C ). These results show that BGP expression is not restricted to osteoblasts: It is expressed in other cell types capable of producing mineralized matrix, such as chondrocytes and VSMCs.
BGP Promotes Differentiation and Mineralization of ATDC5 and MOVAS Cells
To study the role of BGP in chondrogenic-like differentiation, we stably overexpressed the full-length BGP in ATDC5 and MOVAS cells and compared them to control cells transfected with empty vectors. In BGP-overexpressing ATDC5 and MOVAS cells, BGP mRNA and protein levels were significantly higher at all time points tested than in their respective control cells ( Figure 3A, B) . BGP overexpression significantly accelerated the differentiation and mineralization of both ATDC5 and MOVAS cells, as evidenced by higher intensities of staining for mineral deposits, proteoglycans, and ALP activity ( Figure 3C and 3E) . The intensities of the stains were similarly low on day 1 and increased throughout differentiation, with BGP-overexpressing cells showing significantly higher staining compared to control cells from day 7 to day 21. To eliminate the possibility of reflexive mineral deposition due to higher levels of BGP (known to bind hydroxyapatite), we further investigated the effect of BGP overexpression on osteochondrogenic differentiation markers. BGP overexpression induced the expression of Sox9, Runx2 and collagen type X in both cells. The expression of collagen type II mRNA was also upregulated in BGP-overexpressing ATDC5 cells but reduced in BGP-overexpressing MOVAS cells ( Figure 3D and 3F). The expression of smooth muscle markers was reduced in both cell types (Supplemental Figure I , available at http://atvb.ahajournals.org). These findings suggest that BGP stimulates differentiation and mineralization of ATDC5 and MOVAS cells by inducing the transcription of osteochondrogenic factors.
BGP Augments Metabolic Cleavage of XTT and Increases Glucose Uptake in ATDC5 and MOVAS Cells
While monitoring ATDC5 and MOVAS cell differentiation in culture, we noticed that BGP-overexpressing cells readily
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convert the color of phenol red-supplemented medium from pink to yellow, indicating lower pH levels and a potentially higher metabolic profile in these cells. Thus, we studied the effect of BGP overexpression on the metabolic activity of ATDC5 and MOVAS cells by XTT assay. Indeed, BGP cells showed higher levels of XTT cleavage over a range of cell densities, compared to empty vector overexpressing controls ( Figure 4A ). This increase in metabolic profile could either trigger or be caused by increased cellular proliferation. When plated at equal densities and observed the next day, BGPoverexpressing ATDC5 and MOVAS cells showed higher densities than controls ( Figure 4B ). These data, together with the suggested role of BGP in glucose sensitivity, 16 -20 led us to check whether BGP-induced upregulation of metabolism is associated with increased handling of glucose. BGP overexpression stimulated glucose-uptake rate, as shown by a higher number of fluorescent cells resulting from an increased influx of 2-NBDG ( Figure 4C ). To further quantify these data, we measured fluorescence intensity by FACS and, plotting average FL1 intensity, corrected for the maximal innate fluorescence of cells in the absence of 2-NBDG ( Figure 4D ). Because the metabolic effect of BGP in transgenic mice models was previously attributed to the uncarboxylated form, we generated BGP mutant with inability to undergo ␥-carboxylation. Nevertheless, uncarboxylated BGP mutant lost its metabolism and differentiation stimulating function, compared wild type BGP, possibly due to improper protein folding (Supplemental Figure II) . Collectively, these results showed that BGP induces the metabolic activity of ATDC5 and MOVAS cells by directly increasing glucose uptake.
BGP Upregulates Genes of Glucose Transport and Utilization via Stabilization of HIF-1␣ Protein in ATDC5 and MOVAS Cells
Next, we investigated whether the stimulatory effects of BGP on differentiation and metabolism coincide with alterations in metabolic status. Throughout the course of differentiation in culture, BGP overexpression increased the mRNA levels of facilitative glucose transporter GLUT1 in ATDC5 cells and insulin-dependent glucose transporter GLUT4 in MOVAS cells compared to the control cells ( Figure 5A, B) . Moreover, BGP overexpression upregulated the expression of key glycolysis enzymes-PFK 1 and PDK1, while decreasing the mRNA expression of key gluconeogenesis enzymes-phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, in both cell types ( Figure 5A and 5B) . In a search for plausible factors capable of mediating the BGP-triggered glycolytic flux, we tested the expression of HIF-1␣, well known to activate glycolysis in cancer cells. 23 Baseline protein expression of HIF-1␣ was very low in ATDC5 and MOVAS cells, increasing with time. Stable BGP overexpression increased the levels of HIF-1␣ subunit protein in both cell lines from day 7 throughout the rest of the differentiation Figure 5C ). To validate the immediate metabolic capacity of BGP, we used another in vitro model, in which wild-type ATDC5 and MOVAS cells were treated with purified bovine BGP. Within 5 to 10 minutes of exposure, exogenous BGP resulted in activation of the insulin-signaling pathway, as shown by elevation in phosphorylated forms of insulin receptor, insulin receptor substrate 1, and Akt ( Figure   5D ). These results demonstrated that BGP is capable of inducing metabolic changes in chondrocytes and VSMCs during long-term and short-term exposure regimens. To test whether HIF-1␣ stabilization is essential in mediating the metabolic effects of BGP, we silenced HIF-1␣ using siRNA. Because HIF-1 is recognized as a chondrogenesis survival factor, 21, 24 we refrained from blocking its activity during the long-term differentiation schedule and used the short-term model. Although treatment with purified BGP resulted in elevation of HIF-1␣ protein and mRNA within 5 to 10 minutes, silencing of HIF-1␣ counteracted this effect in both ATDC5 and MOVAS cells ( Figure 6A, B, C) . Because HIF-1 has been shown to modulate GAPDH expression, 23 we used ␤-actin as the housekeeping protein ( Figure 6A ). Next, we explored whether exogenous addition of BGP affects the expression of glucose-metabolism genes, as seen in the overexpression models. Treatment of scrambled siRNAtransfected cells with purified BGP resulted in timedependent upregulation of PFK, PDK1, GLUT1, insulin receptor, and insulin receptor substrate 1 mRNA, whereas silencing of HIF-1␣ prevented this response in ATDC5 cells ( Figure 6B ). Similar results were obtained in MOVAS cells, where downregulation of HIF-1␣ suppressed BGP-mediated elevation of metabolism-related genes, with exception of GLUT4 instead of GLUT1 ( Figure 6C ). Taken together, these results demonstrate that BGP functions as a glucose metabolism-modulating factor, stimulating HIF-1␣-dependent glucose uptake and utilization in chondrocytes and VSMCs.
1,25(OH) 2 D 3 -Induced Increase in BGP Correlates with Upregulated Expression of HIF-1␣ in Aortas and Tibial Growth Plates of Young Rats
The mechanism of BGP-stimulated stabilization of HIF-1␣ lead us to test whether higher BGP levels correlate with higher HIF-1␣ and PFK levels in the animal model described in Figure 1 . Immunohistochemical staining showed increased HIF-1␣ protein ( Figure 7A ), and ISH showed upregulation of PFK mRNA in the aortas of the 1,25(OH) 2 D 3 -treated group relative to the control group ( Figure 7B ). Concomitant with upregulated BGP, treatment with 1,25(OH) 2 D 3 increased HIF-1␣ protein in the tibial growth plates, expanding its expression from the prehypertrophic and hypertrophic chondrocytes of the control group to the proliferating zone in the 1,25(OH) 2 D 3 -treated group ( Figure 7A ). The expression pattern of HIF-1␣ was analogous to the protein expression pattern of BGP. Real-time mRNA analysis demonstrated upregulated HIF-1␣ expression, coinciding with elevated PFK, PDK1, and GLUT1 level, supporting the altered metabolic status of calcified aortas ( Figure 7C ). HIF-1␣ is widely recognized for its crucial role in cartilage formation and survival. 24 To strengthen the link between HIF-1␣ and differentiation, we subjected MOVAS cells to hypoxic stress or treatment with CoCl 2 , known to mimic hypoxia. Both treatments stabilized HIF-1␣ protein, shown by Western blot analysis, and increased the mRNA expression of PFK, Runx2, and collagens type II and X and reduced contractile ␣sm-actin marker ( Figure 7D and 7E) . In contrast, siRNA silencing or pharmacological inhibition of HIF-1␣ on the background of CoCl 2 reduced the expression of osteochondrogenic markers in MOVAS ( Figure 7F , Supplemental Figure III ), suggesting that via HIF-1␣, BGP augments VSMC osteochondrogenic profile.
BGP Mediates 1,25(OH) 2 D 3 -Induced HIF-1␣ Stabilization and Vascular Calcification in Young Rats
The 1,25(OH) 2 D 3 -induced model of aortic mineralization in young rats pointed toward a strong correlation between elevated BGP, HIF-1␣, and a shift toward glycolytic glucose utilization. To further challenge the hypothesis and clarify whether the metabolic and differentiation effects are indeed reliant on BGP, we established a model where BGP is siRNA-silenced in young rats receiving 1,25(OH) 2 D 3 treatment. Real-time PCR and ISH analyses reveal dramatic reduction of BGP mRNA expression in the tibiae VD ϩBGP siRNA group compared to VD ϩsc siRNA control group (Figure 8A, E) . BGP mRNA reduction was also observed in the aortas of BGP-silenced rats ( Figure 8E ). This effect was translated into suppressed BGP protein levels ( Figure 8B, D) , which prevented HIF-1␣ stabilization in the tibial growth plates and aortas, shown by immunohistochemistry ( Figure  8B, D) . Notably, silencing of BGP counteracted the increase in Sox9 and HIF-1␣ mRNA expression previously shown to be elevated by 1,25(OH) 2 D 3 stimulation ( Figure 1C ) and significantly reduced the vascular calcification Alizarin Red and Von Kossa staining ( Figure 8C ). In addition to cardiovascular effects, micro-CT analysis of VD ϩ BGP siRNA bones revealed elevated cortical porosity density and diminished trabecular bone parameters (Supplemental Figure IV) . These results show that BGP mediates 1,25(OH) 2 D 3 -induced HIF-1␣ stabilization in the aortas and growth plates of young rats, supporting the in vitro evidence for the role of BGP in the progression of cartilage and vascular calcification.
Discussion
To the best of our knowledge, this is the first study demonstrating BGPs function as a stimulator of differentiation and mineralization in chondrocytes and VSMCs. We show a novel mechanism whereby BGP locally induces glucose uptake and utilization in chondrocytes and VSMCs in a HIF-1␣-dependent manner, evident in both the short-term treatment and the long-term overexpression time frames. Moreover, this is a first evidence of in vivo siRNA approach to knock-down BGP in bone and vasculature, counteracting 1,25(OH) 2 D 3-induced vascular calcification. Overall, our study suggests an integrative role of BGP in the modulation of cell metabolism and stimulation of matrix calcification (Figure 9 ). Numerous data from vascular calcification in patients and rodents reveal the presence of BGP in the vicinity of calcified plaques. 12, 37 Because vascular calcification is suggested to arise from loss of constitutive mineralization inhibitors and appearance of calcification inducers, 1, 2, 5 we hypothesized that BGP may function as such inducer. First, we demonstrated that BGP level increases with osteochondrogenic differentiation in two different cell lines, chondrocytes and VSMCs, and second, we showed that when overexpressed, BGP functions as a stimulator of differentiation and mineralization, upregulating Sox9, Runx2, collagen type X, ALP, proteoglycans, and mineral content in both of these cells. We also showed a correlation between aortal calcification and elevation of BGP in 1,25(OH) 2 D 3 -treated rats, which was hampered by BGP siRNA silencing. Although, BGP-deficient mice appeared to have no dramatic skeletal abnormalities, 16 our observations are supported by a study reporting altered bone mechanical properties and matrix crystallinity in these mice. In the mentioned work, BGP was suggested to have a role in the growth of hydroxyapatite crystals via an increase in the degree of carbonate substitutions. 38 Moreover, studies conducted in Ciprinus carpio (carp) rib bone showed a positive correlation between BGP and mineralization, 39 as well as enhanced binding to hydroxyapatite in the presence of calcium. 40 Collectively, these and our observations suggest that BGP is not a passive outcome of the mineralization process, but rather an active contributor, stimulating the differentiation and mineralization of chondrocytes and VSMCs.
A recent breakthrough in the field of bone physiology identified skeleton as an endocrine organ that regulates energy metabolism via the secretion of BGP from osteoblasts. 14, 15 BGP gene-deficient mice appeared obese, hypoinsulinemic, and hyperglycemic, 18 whereas continuous delivery of recombinant BGP to wild-type mice resulted in improved glucose handling and reduced fat mass. 17 These studies demonstrated the systemic role of BGP in the regulation of energy metabolism, acting on pancreas and adipose tissue, a notion that led us to suggest that increased mineralization may stem from BGP-altered metabolic activity. We report that both transfected and purified BGP directly induce glucose uptake by stimulating the expression of the facilitative glucose transporters, GLUT1 and GLUT4, as well as by inducing the insulin-signaling pathway in chondrocytes and VSMCs. Two recent papers showed that insulin signaling in osteoblasts stimulates BGP production and activation, thus promoting further insulin release in a feed-forward loop. 41, 42 It is plausible that the enhancing effects of BGP on insulin signaling presented here contribute to this feed-forward loop not only systemically, but also locally. Beyond glucose influx, we also showed that BGP upregulates glycolytic breakdown of glucose by stimulating the expression of PFK and PDK1. Whereas PFK is the rate-limiting glycolytic enzyme, catalyzing the irreversible conversion of fructose-6- Figure 9 . Proposed mechanism of action of Bone Gla Protein (BGP)on glucose metabolism and mineralization. Vitamin D stimulates bone BGP production, which diffuses into the neighboring growth-plate and is released into the circulation. Vitamin D also stimulates local BGP production in the vasculature. At the level of chondrocyte and VSMC, BGP stabilizes the hypoxia sensitive HIF-1␣ subunit leading to an increased rate of glucose uptake. Glucose flux is stimulated by transactivation of facilitative glucose transporters GLUT1 and GLUT4 and activation of insulin signal transduction cascade, including phosphorylation of IR, IRS-1 and Akt. Inside the cell, via HIF-1 stabilization, BGP channels glucose into the glycolytic pathway by increasing the expression of key enzymes PFK and PDK1, switching off the mitochondrial oxidative phosphorylation and stimulating less efficient (only 2 moles of ATP), but much faster conversion of glucose into energy. Concomitant with elevation of glycolysis, BGP suppresses the expression of key gluconeogenesis enzymes, glucose-6-phosphatase (G6Pase), and phosphoenolpyruvate carboxykinase (PEPCK). Altered metabolic status translates into augmented chondro-osteogenic differentiation state, contributing to the development of cartilage and vascular calcification. phosphate to fructose-1,6-bisphosphate, PDK1 functions to inactivate pyruvate dehydrogenase (PDH), thus blocking the flow of pyruvate into the mitochondria for oxidative phosphorylation. 21 Therefore, BGP-induced elevation of PFK and PDK1 enzyme levels indicates metabolic conversion to the glycolytic breakdown of glucose. Concomitant with increased glycolysis, we also demonstrated that BGP inhibits the opposite process of gluconeogenesis, by decreasing the expression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase enzymes. Our in vitro data were supported by the in vivo observation of accumulated PFK and PDK1 expression in the calcified, BGP-rich aortas of 1,25(OH) 2 D 3treated rats, prevented by in vivo silencing of BGP. These results also correlate with findings by Lee and colleagues, where BGP-deficient mice exhibited increased phosphoenolpyruvate carboxykinase expression in the liver and decreased insulin target genes in the skeletal muscle, on the background of overall glucose intolerance. 18 Although data obtained from transgenic animals points to endocrine cross-talk between bone, pancreas, and fat, we show that secreted BGP has additional autocrine, paracrine, and endocrine actions, directly stimulating energy metabolism in the neighboring chondrocytes and the more remote VSMCs.
During the physiological process of chondrogenesis, the microenvironment in the cartilage condensations becomes hypoxic 4 ; HIF-1 acts as a survival factor, 22 providing necessary adaptation to the physiologically low oxygen tension. Animal and clinical studies find a direct correlation between local arterial wall hypoxia, atherosclerosis, and VSMC proliferation. 4, 43 Moreover, HIF-1 was found in the calcified plaques of coronaries from renal patients, 37 supporting a relationship between hypoxia and vascular calcification. Our results revealed a direct link between BGP and HIF-1␣ stabilization in the in vitro chondrocyte and VSMC models of BGP overexpression and treatment with purified protein. Moreover, we showed a direct in vivo link between BGP and HIF-1␣ in the calcified aortas of 1,25(OH) 2 D 3 -treated rats, where increased BGP levels coincide with elevation of HIF-1␣ and vice versa. The well-documented evidence for the role of HIF-1␣ comes from cancer research, where adaptations to a hypoxic environment involve stabilization of HIF-1␣ and a shift toward glycolytic metabolism, providing tumors with a growth advantage. 23, 44 Using the siRNA silencing approach, we demonstrated that HIF-1␣ is necessary for the direct induction of glucose uptake and utilization by BGP in chondrocytes and VSMCs. Additionally, by subjecting cells to hypoxia we showed that HIF-1␣ stabilization augments the osteochondrogenic transformation of VSMCs. Consistent with our data, analysis of HIF-1␣-deficient mice showed decreased PGK mRNA expression in growth plates 24 and increased HIF-1␣ activity in VHL null mice which led to generalized expression of PGK mRNA throughout the whole growth plate. 45 In addition to effects on glycolysis, HIF-1␣ was shown to stimulate cartilage survival via induction of Sox9, a master regulator of chondrogenesis. In view of the hypoxic nature of mineralized matrix-producing chondrocytes, this novel interaction of BGP with HIF-1␣ suggests a link between the metabolic shift toward glycolytic (anaerobic) breakdown of glucose and stimulation of differentiation and mineralization.
A clinical manifestation of the close relationship between metabolism and mineralization is particularly evident in diabetes mellitus, where both reduced mineral density in the bone and vascular calcification are common. 6, 46 A recent report showed that high glucose induces the expression of Runx2, ALP, and BGP in bovine SMCs, accompanied by increased calcium deposition, whereas another study demonstrated high insulininduced calcium deposition in human VSMCs. 46 Moreover, in genetically modified mice, induction of type II diabetes activates expression of developmental osteogenic transcription factors and proteins in the ascending aorta. 6 The presence of regulatory proteins with opposing functions is a general feature of calcified matrix formation. Along with excess intracellular calcium, matrix vesicles originating from VSMCs and chondrocytes are known to contain the mineralization inhibitor Matrix Gla Protein and mineralization inducer ALP. 4 Similar to BGP, Matrix Gla Protein belongs to the family of Gla proteins that undergo posttranslational vitamin K-dependent ␥-carboxylation of three glutamate residues. It has been suggested that impaired balance of mineralization potentiators and inhibitors, such as an undercarboxylated form of Matrix Gla Protein, leads to accelerated vascular matrix calcification. 2, 5 An additional Gla protein, Gas6, and its receptor Axl, were also shown to play a pivotal role in mediating antiapoptotic and antimineralizing effects of statins in VSMCs. 47 Moreover, Gas6-Axl signaling was shown to be regulated by glucose via Akt and mTOR, further supporting the contribution of metabolism in diabetic VSMC dysfunction. 48 Thus, consistent with this mechanism, BGP may function as a regulatory protein, modulating VSMC and chondrocyte calcification potential in response to extracellular calcium and a phosphate environment.
Interestingly, several clinical intervention studies have suggested that vitamin D itself, along with 1,25(OH) 2 D 3, affects glucose metabolism. 34 Vitamin D-deficient patients have reduced insulin secretion, whereas vitamin D treatment restores glucose tolerance. Moreover, pancreatic islets from vitamin D-deficient animals exhibit impaired insulin release when challenged with glucose, whereas high concentrations of 1,25(OH) 2 D 3 reverse these abnormalities, by increasing insulin release and action. 34 We demonstrated that 1,25(OH) 2 D 3 treatment of young rats results in elevation of the glucose metabolism-regulating factors BGP, HIF-1␣, GLUT1, PFK, and PDK1 suggesting an additional mechanism by which vitamin D controls glucose tolerance. The present study shows that a higher level of bone and vasculature-produced BGP exerts both systemic and local metabolic effects that influence cartilage and vascular mineralization.
